Member Content

M&A Analysis – Biotech – Oncology – October 2020

by Joe Kunkle | Oct 1, 2020

Immunomedic (IMMU) a notable deal in Biotech at a value of $21B and coming at a sizable 108% premium from Gilead (GILD) with M&A in Biotech continuing to favor deals in the Oncology space. The large cap Biotech’s continue to generate strong cash ...

Please login to continue reading this article.

Options Hawk Max

$399 | 30 days

Options Hawk Trading Hub Live Chat
Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
Live Mock Portfolio
1 on 1 Access
Hawk’s Trader Toolbox
Street Research
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
Weekly and Monthly OpEx Sheets
Notable Options Database
OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$199 | 30 days

Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
OptionsHawk Quarterly Market Brief

More About this Plan